Credential Securities’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q2
$437K Sell
18,944
-1,414
-7% -$33.6K 0.1% 121
2018
Q1
$501K Sell
20,358
-124
-0.6% -$3.26K 0.12% 119
2017
Q4
$550K Sell
20,482
-6
-0% -$153 0.13% 118
2017
Q3
$493K Sell
20,488
-1,040
-5% -$23.5K 0.13% 121
2017
Q2
$457K Buy
21,528
+20,114
+1,422% +$406K 0.14% 121
2017
Q1
$24.2K Buy
1,414
+1,030
+268% +$17.9K 0.01% 228
2016
Q4
$6.88K Hold
384
﹤0.01% 228
2016
Q3
$7.98K Buy
384
+300
+357% +$7.44K ﹤0.01% 218
2016
Q2
$2.26K Buy
84
+34
+68% +$932 ﹤0.01% 215
2016
Q1
$1.35K Sell
50
-22,650
-100% -$607K ﹤0.01% 214
2015
Q4
$659K Buy
22,700
+656
+3% +$18.2K 0.43% 76
2015
Q3
$598K Buy
22,044
+86
+0.4% +$2.44K 0.42% 75
2015
Q2
$601K Buy
21,958
+428
+2% +$12K 0.38% 81
2015
Q1
$575K Sell
21,530
-9,852
-31% -$227K 0.37% 86
2014
Q4
$664K Buy
31,382
+15,078
+92% +$337K 0.43% 72
2014
Q3
$394K Buy
16,304
+884
+6% +$20.3K 0.26% 105
2014
Q2
$356K Buy
15,420
+1,444
+10% +$31.9K 0.24% 108
2014
Q1
$319K Buy
+13,976
New +$298K 0.24% 106

Other funds holding NVO

Credential Securities's NVO Position: Q2 2018 in Review

Credential Securities reduced its Novo Nordisk (NVO) stake by 6.9% in Q2 2018, selling an estimated $33.6K and leaving 18,944 shares worth $437K. The position accounts for 0.1% of the portfolio, ranked #121.

Credential Securities first reported a position in NVO in Q1 2014 and has held it in 18 quarters since. The position peaked at $664K in Q4 2014. 537 funds tracked by Wall St. Rank hold NVO as of Q2 2018.

  • Credential Securities held 18,944 shares of Novo Nordisk worth $437K as of Q2 2018.
  • Credential Securities sold 1,414 Novo Nordisk shares in Q2 2018, an estimated $33.6K.
  • Novo Nordisk made up 0.1% of Credential Securities's portfolio in Q2 2018, its #121 holding.
  • Credential Securities first reported a position in Novo Nordisk in Q1 2014 and has held it in 18 quarters since.
  • Credential Securities's Novo Nordisk position peaked at $664K in Q4 2014.
  • 537 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2018.

Based on Credential Securities's 13F filing for Q2 2018, filed 21 Jul 2025.